Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

Benzinga
2025.10.27 13:37
portai
I'm PortAI, I can summarize articles.

新澤西州弗洛漢公園，2025 年 10 月 27 日（GLOBE NEWSWIRE）-- Cellectar 生物科學公司（NASDAQ:CLRB），一家專注於癌症治療藥物發現和開發的晚期臨牀生物製藥公司，今天宣佈了美國的消息

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.